Table 1.

Demographic and clinical characteristics of type 2 diabetes mellitus patients

Variables	Mean ± SD (n = 50)
Demographics
Age (years)	53.1 ± 7.42
Sex (M/F), n	28/22
Weight (kg)	72.3 ± 12.25
Height (cm)	161.6 ± 8.76
BMI (kg/m2)	27.7 ± 4.46
DM duration (years)	8.5 ± 6.32
Physical activity levels (MET-min/week)	533.1 ± 436.69
Glycemic control
FBG (mg/dl)	158.2 ± 57.80
PPBG (mg/dl)	223.7 ± 87.67
HbA1c (%)	8.2 ± 1.60
Cardiovascular risk profile
TC (mg/dl)	179.3 ± 34.89
TG (mg/dl)	159.7 ± 88.02
LDL (mg/dl)	104.8 ± 32.74
HDL (mg/dl)	43.9 ± 7.66
VLDL (mg/dl)	27.5 ± 10.77
HR (bpm)	81.6 ± 13.06
SBP (mmHg)	125.5 ± 14.05
DBP (mmHg)	75.8 ± 7.97
WC (cm)	94.7 ± 10.71
WHR	1.0 ± 0.12
BF (%)	28.3 ± 10.35
DM complications (n, n%)
Peripheral neuropathy	6 (12)
Retinopathy	3 (6)
Microalbuminuria	1 (2)
Co-morbidities (n, n%)
Hypertension	20 (40)
Dyslipidemia	28 (56)
Thyroid dysfunction	12 (24)
Musculoskeletal issues	5 (10)
Medications (n, n%)
Metformin	29 (58)
Sulphonylureas	13 (26)
DPP4 inhibitors	4 (8)
β blockers	6 (12)
ACE inhibitors	6 (12)
Calcium channel blockers	1 (2)
Insulin	4 (8)
Statins	9 (18)
Levo-thyroxine	6 (12)
Thiazolidinedione	1 (2)
Dapagliflozin	1 (2)
PPI inhibitors	1 (2)
Glucosidase inhibitor	1 (2)
Gliclazide	1 (2)

M: males; F: females; BMI: body mass index; DM: diabetes mellitus; MET: metabolic equivalent; FBG: fasting blood glucose; PPBG: post-prandial blood glucose; HbA1c: glycosylated hemoglobin; TC: total cholesterol; TG: triglycerides; LDL: low density lipoproteins; HDL: high density lipoproteins; VLDL: very low density lipoproteins; WC: waist circumference; WHR: waist-hip ratio; BF: body fat; HR: heart rate; DPP4: dipeptidyl peptidase-4; ACE: angiotensin converting enzyme; PPI: proton pump inhibitor; n: number; %: percentage